TABLE OF CONTENTS
|
| August 2018 Volume 17, Issue 8 |
 | | |
 |  Comment
News and Analysis
Research Highlights
Perspectives
Reviews
Correspondence
| | | Advertisement | | | | 
FREE CASE STUDY:
How Top Biotech & Pharma Companies Manage Their Scientific Data
Are you a scientist? If so, get this free white paper to learn how fast growing companies like viDA Therapeutics are managing their scientific data more effectively and more securely.
Click here to get white paper. | | |
| |
Advertisement |
 |
Expand Your Drug Discovery Pipeline – Targeting Cell Metabolism
Discover novel drug targets for oncology, neurodegeneration, diabetes & cardiovascular disease by targeting energy metabolism. Begin your search for cell metabolism targets arranged by disease indication & build your pipeline now!
Download the guide book to advance your target identification studies. |  | | |
|
| |
| Advertisement |
|
| |
|
| |
| Advertisement |
|
| |
|
| |
Advertisement |
|
Professor Mark Ferguson, Director-General of Science Foundation Ireland explains why he's looking to attract researchers to work in Ireland.
With access to funding from the Irish Government and industry, it's a great time to think about moving.
Read more. *ad feature | | |
|
| |
Comment | |
|
 |
|
| INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology pp529 - 530
Sean Khozin, Richard Pazdur & Anand Shah
doi:10.1038/nrd.2018.34
Information Exchange and Data Transformation (INFORMED), a multidisciplinary initiative anchored in the FDA Oncology Center of Excellence, is a decentralized science and technology incubator designed to harness the power of big data and advanced analytics to improve disease outcomes. |
|
News and Analysis | |
|
|
|
| Constrained peptides' time to shine? pp531 - 533
Chris Morrison
doi:10.1038/nrd.2018.125
Constrained peptides have long tantalized drug developers with their potential ability to combine the best attributes of antibodies and small molecules. Finally, a handful of constrained peptides are in late-stage clinical trials. |
|
|
| News in Brief |
|
|
|
| A snapshot of lead-generation strategies p534
Asher Mullard
doi:10.1038/nrd.2018.129 |
|
|
|
| REVAMPing antibiotic incentives p534
Asher Mullard
doi:10.1038/nrd.2018.130 |
|
|
|
| FDA approves first marijuana-derived product p534
Asher Mullard
doi:10.1038/nrd.2018.131 |
|
|
| Biobusiness Briefs |
|
|
|
| Regulatory watch: FDA new drug approvals in Q2 2018 pp536 - 537
Lisa Urquhart
doi:10.1038/nrd.2018.126 |
|
|
| An Audience With |
|
|
|
| Saurabh Saha pp538 - 539
doi:10.1038/nrd.2018.127
Saurabh Saha, head of Translational Medicine at Bristol-Myers Squibb, discusses how new tools are opening up translational opportunities in immuno-oncology |
|
|
| From the analyst's couch |
|
|
|
| The haemophilia drug market pp541 - 542
Kerri Brown & Graeme Green
doi:10.1038/nrd.2018.54
This article discusses the market for therapies for haemophila, which is forecast to change substantially with the recent launch of emicizumab and the potential future approvals of gene therapies and non-factor treatments. |
|
| Advertisement |
|
Focus on Autoimmune Disease from Nature Immunology
A series of Reviews specially commissioned by Nature Immunology discuss the genetic, environmental, microbial and cellular factors underpinning autoimmune disease as well as highlight avenues for therapeutic intervention.
Access free online
Produced with support from
Janssen Research & Development | | | |
|
| |
Research Highlights | |
|
| |
| Advertisement |
|
Nature Reviews Reader Survey
At Nature Reviews we are continually looking for ways to ensure we meet our readers' needs. Your responses to this short survey will give us insight into how our content may be improved.
Get started here. | | | |
|
| |
|
 |
Perspectives | |
|
|
| Opinion |
|
|
|
| Principles for targeting RNA with drug-like small molecules pp547 - 558
Katherine Deigan Warner, Christine E. Hajdin & Kevin M. Weeks
doi:10.1038/nrd.2018.93
Recent studies have indicated the potential to develop small-molecule drugs that act on RNA targets, leading to burgeoning interest in the field. This article discusses general principles for discovering small-molecule drugs that target RNA and argues that the overarching challenge is to identify appropriate target structures in disease-causing RNAs that have high information content and, consequently, appropriate ligand-binding pockets. |
|
Reviews | |
|
|
|
| The expanding role of prodrugs in contemporary drug design and development pp559 - 587
Jarkko Rautio, Nicholas A. Meanwell, Li Di & Michael J. Hageman
doi:10.1038/nrd.2018.46
Prodrug strategies can be used to overcome pharmacokinetic and pharmacodynamic issues in many therapeutic agents. Here, Rautio and colleagues discuss which approaches have been most successful, particularly in the past 10 years, and highlight the challenges in incorporating prodrug moieties during drug development. |
|
|
|
| Targeting the NLRP3 inflammasome in inflammatory diseases pp588 - 606
Matthew S. J. Mangan, Edward J. Olhava, William R. Roush, H. Martin Seidel, Gary D. Glick et al.
doi:10.1038/nrd.2018.97
The inflammasome is a key integration point for innate immunity. As such, targeting this signalling hub has the potential to be useful in numerous autoimmune and metabolic disorders. In this article, Latz and colleagues discuss the progress that has been made towards targeting the inflammasome, highlighting the therapeutic potential of some of these compounds as well as caveats for their use. |
|
Correspondence | |
|
|
|
| Concerns, challenges and promises of high-content analysis of 3D cellular models p606
Neil Carragher, Filippo Piccinini, Anna Tesei, O. Joseph Trask Jr, Marc Bickle et al.
doi:10.1038/nrd.2018.99 |
|
| Advertisement |
|
nature.com webcasts
Nature Research Custom presents a webcast on: Molecular imaging reveals ONC201 antitumor efficacy and immune stimulation in cancer models
Date: Wednesday, August 15, 2018
Join our live webcast to learn about the benefits of cell culture, xenograft tissue sections and mouse models coupled with imaging in preclinical immuno-oncology trials.
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content
Register for FREE
Sponsored by:
Perkin Elmer | | | |
|
| |
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | |
|
No comments:
Post a Comment